The European Commission granted conditional marketing authorization to ExCellThera’s Zemcelpro, a cord blood-derived cell therapy designed for blood cancer patients lacking matched donors. Zemcelpro represents the first approved cell therapy in Europe for this patient population and the second globally. This milestone underscores the therapeutic potential of cord blood sourcing in hematologic malignancies, providing a novel treatment option for patients with limited donor availability.